Universal DX

Universal DX (UDX), incorporated in Spain in 2012 and headquartered in Madrid, develops cell-free DNA blood tests for early cancer detection. Its lead assay, Signal-C, uses next-generation sequencing of methylation and fragmentation patterns in circulating DNA with machine learning to detect colorectal cancer and advanced adenomas. In a 1,000-patient study at Digestive Disease Week 2023 it showed 93 percent sensitivity for colorectal cancer and 54 percent for advanced adenomas at 92 percent specificity. A 15,000-patient, 100-site FDA registrational trial (NCT06059963) enrolled its first patient in January 2024, with Quest's Lewisville, Texas laboratory as the single testing site. UDX announced a Series B initial close of about $70 million in November 2023 including Quest, completed in August 2024 with new investor Olympus Innovation Ventures.